Seqirus, part of the CSL Limited Group, has already begun the distribution of the doses of the flu vaccine that will be administered by the Italian Regions to citizens starting in the next few weeks. The company announces it in a note, recalling that “the start of the flu vaccination campaign for the 2021-2022 season is just a short distance away. The timing is given by Aifa which authorizes the updating of the composition of flu vaccines. And it will be essential that, at the start of immunization, the doses of vaccine necessary to take off the important prevention initiative, offering targeted responses based on the characteristics of the subjects “.
“Seqirus has always been at the forefront in the fight against influenza and makes all its skills available to continue being an excellent partner of Italian public health – he declares Maura Cambiaggi, General Manager Seqirus Italy – We are proud to have made a significant contribution last year to achieving high coverage rates and we are confident that equally positive results can be achieved this season as well. For us it is a priority to protect citizens from flu viruses and the vaccines required by the Regions are already being delivered, in full compliance with the times recommended by the circular of the Ministry of Health – he underlines – in order to protect as soon as possible the most fragile categories such as the elderly in a difficult epidemiological situation“.
Influenza protection, the company remarks, “will be fundamental this season also in consideration of the persistence of the Sars-Cov-2 pandemic, and may allow relieve the pressure on the national health system already strongly tried by the Covid-19 pandemic, as well as favor differential diagnosis especially in the most vulnerable subjects. Furthermore, multiple recently published studies suggest that influenza vaccination can help mitigate the serious complications caused by Covid-19, facilitating a more favorable course of the disease “.
For Seqirus “the important thing is to offer a ‘tailor-made’ answer for everyone. This is why we must remember that not all vaccines are the same “, the company specifies.
“The functioning of our immune system – he explains – is in fact based on a complex mechanism of interaction between a multiplicity of different cells involved in creating an efficient defense system of the organism against foreign agents. The cells of the immune system, with the advancing age, undergo a progressive biological aging process, known as immunosenescence. Among other things, there is a decrease in the functioning of T and B lymphocytes: the changes that occur at the cellular level are reflected in the reduction of the ability to produce an adequate immune response in the elderly. For this reason it is essential to offer each person the most suitable vaccine for their characteristics, based on their age and the presence of any concomitant diseases “.
“Scientific research is moving increasingly towards precision medicine also applied to vaccines and Seqirus, thanks to its cutting-edge research and development capacity and its portfolio of differentiated products – concludes the company – will make available for the campaign influenza 2021-2022 both the new adjuvanted quadrivalent vaccine, specifically indicated for the active prophylaxis of influenza in subjects over 65 years of age, and the quadrivalent vaccine produced on cell cultures and indicated from 2 years of age “.